-- Presentation to be webcast on www.exelixis.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 29, 2017--
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s President and Chief Executive Officer, will provide
an overview of the company at the Morgan Stanley Global Healthcare
Conference taking place September 11-13 in New York, NY. The Exelixis
presentation is scheduled for 11:40 AM EDT / 8:40 AM PDT on Wednesday,
September 13, 2017.
The presentation will be webcast live and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
Please connect to the company’s website at least 15 minutes prior to the
presentation to ensure adequate time for any software download that may
be required to listen to the webcast. A replay will also be available at
the same location for 14 days.
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed
to the discovery, development and commercialization of new medicines to
improve care and outcomes for people with cancer. Since its founding in
1994, three products discovered at Exelixis have progressed through
clinical development, received regulatory approval, and entered the
marketplace. Two are derived from cabozantinib, an inhibitor of multiple
tyrosine kinases including VEGF, MET, AXL and RET receptors: CABOMETYX®
tablets approved for previously treated advanced renal cell carcinoma
and COMETRIQ® capsules approved for progressive, metastatic
medullary thyroid cancer. The third product, COTELLIC®, is a
formulation of cobimetinib, a reversible inhibitor of MEK, is marketed
under a collaboration with Genentech (a member of the Roche Group), and
is approved as part of a combination regimen to treat advanced melanoma.
Both cabozantinib and cobimetinib have shown potential in a variety of
forms of cancer and are the subjects of broad clinical development
programs. For more information about Exelixis, please visit www.exelixis.com
or follow @ExelixisInc on Twitter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170829006082/en/
Source: Exelixis, Inc.
Susan Hubbard, 650-837-8194
EVP, Public Affairs
& Investor Relations
Hal Mackins, 415-994-0040